Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.

Status:
Completed
Trial end date:
2012-12-03
Target enrollment:
Participant gender:
Summary
A single blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic parameters of repeat doses of GSK2330672 in healthy volunteers, given alone and with a single day of dosing with GSK1614235
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline